Psoriasis--new insights into pathogenesis and treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19564982.
- Also identified by DOI 10.3238/arztebl.2009.0011 and PMC identifier PMC1474031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
BACKGROUND: Psoriasis is one of the most prevalent chronic inflammatory diseases, affecting approximately 2 million people in Germany. METHODS: Selective literature review taking into account the German S1 and S3 guidelines for the treatment of this condition. RESULTS AND CONCLUSIONS: Psoriasis is a very troublesome disease with a high economic impact. The disease often persists for life, and the patient has an increased risk of cardiovascular diseases and their complications. One out of five patients develops psoriatic arthritis. The clinical picture of psoriasis is highly variable with regard to lesional characteristics and the severity of disease. To improve the management of psoriasis the guidelines must be followed and all appropriate topical and systemic treatment options must be tried, with clearly defined treatment goals. The spectrum of established systemic treatments for psoriasis has been extended by the biologics. These can be used to achieve a good skin status and a clear-cut improvement in quality of life even in patients who do not--or no longer--respond adequately to conventional therapies.